

- **Name:** Sun Young Rha
- **Current Position:** Professor of Medical Oncology, Internal Medicine
- **Country:** Korea

- **Educational Background:**

MD, PhD at Yonsei University College of Medicine
Clinical and Research Fellow of Medical Oncology at Yonsei Cancer Center,
Yonsei University Health System
Post-doctoral fellow at Cancer Therapy and Research Center
Institute for Drug Development
The University of Texas Health Science Center at San Antonio

- **Professional Experience:**

Assistant professor at the Cancer Metastasis Research Center, Yonsei Cancer Center
Associate Professor, Medical Oncology, Internal Medicine, Yonsei University college of Medicine
Chief, Division of Genomics and Translational Research,
Cancer Metastasis Research Center, Yonsei University College of Medicine
Director, Human research Protection Center, Severance Hospital

- **Professional Organizations:**

Chair, Academic Committee of Korean Cancer Society (KCA)
Executive Board Member, chair of Translational Research Committee, Korean Cancer Study Group
Vice President of Korean Gastric Cancer Society
Vice President of Korea Genome Organization
Chair, Planning Committee of Korean Association of IRB
Board member of Korean Society of Medical Oncology

- **Main Scientific Publications:**

Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park SM, Beom SH, Kim HS, Cheong JH, Chung HC, Soong J, Lin SC, Rha SY. *Gastric Cancer*. 2019 May 16.

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. Lee JB, Park HS, Park S, Lee HJ, Kwon KA, Choi YJ, Kim YJ, Nam CM, Cho NH, Kang B, Chung HC, Rha SY. *Cancer Res Treat*. 2019 Apr 16.

Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. Kim C, Chon HJ, Kim JH, Jung M, Nam CM, Kim HS, Kang B, Chung HC, Rha SY. *Eur J Cancer*. 2019 May;112:20-28.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H. *J Immunother Cancer*. 2019 Feb 4;7(1):30.

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial. Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, Jung M, Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC). *Clin Cancer Res*. 2018 Nov 1;24(21):5272-5281.

Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer. Jeong I, Kang SK, Kwon WS, Kim HJ, Kim KH, Kim HM, Lee A, Lee SK, Bogenrieder T, Chung HC, Rha SY. *J Cell Mol Med*. 2018 Dec;22(12):5899-5908

Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition. Lee SH, Lee WK, Kim N, Kang JH, Kim KH, Kim SG, Lee JS, Lee S, Lee J, Joo J, Kwon WS, Rha SY, Kim SY. *Cancers (Basel)*. 2018 Nov 19;10(11).

Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. Beom SH, Choi YY, Baek SE, Li SX, Lim JS, Son T, Kim HI, Cheong JH, Hyung WJ, Choi SH, Jung M, Kim HS, Jeung HC, Chung HC, Rha SY, Noh SH. *BMC Cancer*. 2018 Nov 15;18(1):1116.

Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY. *Int J Cancer*. 2018 Jul 1;143(1):151-159. .

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK. *Gastric Cancer*. 2018 Sep;21(5):819-830.

A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. Chae D, Nam CM, Kim JH, Lee CK, Kim SS, Kim HS, Jung M, Cheong JH, Chung HC, Rha SY, Park K. *APS J*. 2018 May 29;20(4):72.

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. *Cancer Res Treat*. 2018 Feb 5.

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP. *BMC Cancer*. 2018 Mar 27;18(1):332.

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Kim C, Lee CK, Chon HJ, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY. *Oncotarget* 2017 Dec 9;8(69):113494-113501

Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S. *Oncotarget*. 2017 Jun 13; 8(24):38389-38398

Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H. *Oncotarget*. 2016 Jul 12;7(28):44608-44620.

Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Ooi WF, Xing M, Xu C, Yao X, Ramlee MK, Lim MC, Cao F, Lim K, Babu D, Poon LF, Lin Suling J, Qamra A, Irwanto A, Qu Zhengzhong J, Nandi T, Lee-Lim AP, Chan YS, Tay ST, Lee MH, Davies JO, Wong WK, Soo KC, Chan WH, Ong HS, Chow P, Wong CY, Rha SY, Liu J, Hillmer AM, Hughes JR, Rozen S, Teh BT, Fullwood MJ, Li S, Tan P. *Nat Commun*. 2016 Sep 28;7:12983.

The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Chon HJ, Kim HR, Shin E, Kim C, Heo SJ, Lee CK, Park JK, Noh SH, Chung HC, Rha SY. *Ann Surg Oncol*. 2015 Nov;22(12):3938-45.

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. *Gut*. 2015 Nov;64(11):1721-31.

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY, Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, Zhang Q, Kim JM, Kim YH, Sakata Y. *Gastric Cancer*. 2015 Oct;18(4):824-32.

Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP. *Cancer Chemother Pharmacol*. 2015 Aug;76(2):397-408.